Azitra, Inc. (AZTR)
NYSEAMERICAN: AZTR · Real-Time Price · USD
0.8838
+0.0475 (5.68%)
At close: Nov 3, 2026, 4:00 PM
0.8757
-0.0081 (-0.92%)
After-hours: Nov 3, 2026, 6:05 PM EST
Azitra Employees
Azitra had 13 employees as of December 31, 2025. The number of employees increased by 1 or 8.33% compared to the previous year. That makes Azitra the 39,440th largest employer in the world and 5,839th in the United States.
Employees
13
Change (1Y)
1
Growth (1Y)
8.33%
Revenue / Employee
n/a
Profits / Employee
-$944,072
Market Cap
5.36M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 13 | 1 | 8.33% |
| Dec 31, 2024 | 12 | 2 | 20.00% |
| Dec 31, 2023 | 10 | 0 | - |
| Mar 31, 2023 | 10 | 0 | - |
| Dec 31, 2022 | 10 | 0 | - |
| Sep 30, 2022 | 10 | 0 | - |
| Dec 31, 2021 | 10 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 52 |
| Longeveron | 38 |
| AIM ImmunoTech | 21 |
| Imunon | 20 |
| Cardio Diagnostics Holdings | 17 |
| Traws Pharma | 7 |
| Can-Fite BioPharma | 5 |
| Acurx Pharmaceuticals | 4 |
AZTR News
- 5 days ago - Azitra expands eligibility for Phase 1/2 clinical trial of ATR-04 - TheFly
- 5 days ago - Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial to Include Patients with Rashes due to KRAS and MEK Inhibitors - PRNewsWire
- 8 days ago - Azitra’s ATR-COSF shows skin revitalizing effectivity in ex vivo study - TheFly
- 8 days ago - Azitra, Inc. Announces Revitalizing Results from Ex Vivo Study of ATR-COSF Demonstrating Ability to Reduce Fine Lines and Improve Elasticity in Human Skin - PRNewsWire
- 18 days ago - Azitra announces 1-for-10 reverse stock split - TheFly
- 18 days ago - Azitra, Inc. Announces Reverse Stock Split - PRNewsWire
- 4 weeks ago - Azitra completes Cohort 1 in Phase 1/2 clinical trial evaluating ATR04-484 - TheFly
- 4 weeks ago - Azitra, Inc. Advances ATR-04 Phase 1/2 Clinical Trial to Cohort 2 Following Safety Review Committee Clearance - PRNewsWire